Volume 16, Number 11—November 2010
Research
Lymphotropism of Merkel Cell Polyomavirus Infection, Nova Scotia, Canada
Table 3
Characteristic | No. (%) cases | No. (%) MCPyV positive | No. (%) MCPyV negative |
---|---|---|---|
Patient sex | |||
M | 16 (66.7) | 2 (12.5) | 14 (87.5) |
F |
8 (33.3) |
3 (37.5) |
5 (62.5) |
Patient age, y | |||
<60 | 6 (25.0) | 0 | 6 (100.0) |
>60 |
18 (75.0) |
5 (27.8) |
13 (72.2) |
Disease stage† | |||
I | 9 (40.9) | 1 (11.1) | 8 (88.9) |
II | 5 (22.7) | 3 (60.0) | 2 (40.0) |
III | 0 | 0 | 0 |
IV |
8 (36.4) |
1 (12.5) |
7 (87.5) |
Patient survival‡ | |||
Alive in remission | 2 (15.4) | 1 (50.0) | 1 (50.0) |
Alive with disease | 6 (46.1) | 0 | 6 (100.0) |
Dead from disease |
5 (38.5) |
1 (20.0) |
4 (80.0) |
Total | 24 | 5 (20.8) | 19 (79.2) |
*No patients with chronic lymphocytic leukemia/small lymphocytic lymphoma had Merkel cell carcinoma. MCPyV, Merkel cell polyomavirus.
†Stage of disease for 2 MCPyV-negative patients was unknown.
‡Five-year follow-up survival information. Data were available for 13 patients, excluding 10 who had received a diagnosis within the past 5 y and one who was lost to follow-up. Disease refers to original diagnosis of either lymphoma or leukemia.
Page created: March 08, 2011
Page updated: March 08, 2011
Page reviewed: March 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.